(2-methyl-5-nitrophenyl) nitrate

We are (2-methyl-5-nitrophenyl) nitrate CAS:152460-07-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: (2-methyl-5-nitrophenyl) nitrate
CAS.NO:  152460-07-6
Synonyms:
1-(2-methyl-5-nitrophenyl)guanidine
N-(2-Methyl-5-nitro-phenyl)-guanidine
Guanidine,N-(2-methyl-5-nitrophenyl)
(2-methyl-5-nitrophenyl)guanidine

Molecular Formula: C8H10N4O2
Molecular Weight:194.19100

Physical and Chemical Properties:
Density: 1.432g/cm3
Boiling point: 426.748ºC at 760 mmHg
Melting point:/
Flash point:211.89ºC
Refractive index: 1.646

Specification:
Appearance:Off-white solid
Purity:≥99%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Imatinib mesylate  CAS: 220127-57-1
Intermediates of Imatinib  CAS:152459-95-5

Related News: In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.2,4-difluorofenil isotiocianato CAS:141106-52-7 In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.119-62-0 In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.D-Isoleucine Combining its core technological advantages such as ammonia oxidation, phosgenation, and fluorination, the company actively enters the field of fine and functional chemicals, and expands its focus to include polymer additives, replacement of phenolic polymer material monomers, and coating preservatives.We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries.